FindTrial
Sign In

Study on expression of inflammatory factors in the study on pathogenesis and prevention of high altitude Polycythemia

Study on expression of inflammatory factors in the study on pathogenesis and prevention of high altitude Polycythemia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OCH-14004273
Enrollment
Unknown
Registered
2014-01-26
Start date
2010-01-05
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high altitude Polycythemia

Interventions

HAPC group:none
Early HAPC group:none
Plateau people group:none
Plain normal group:none
Group of early intervention of high altitude Polyc:Isoflavone Capsules
High altitude Polycythemia intervention group:Isoflavone Capsules

Sponsors

Second Affiliated Hospital of Third Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 38 Years

Inclusion criteria

Inclusion criteria: 1. Patients with high altitude Polycythemia diagnosed and early high altitude Polycythemia patients with normal people, plateau, Plains people living in or moved to the Highlands for more than 1 years, young people aged 20-40; 2. According to the 2004 International Congress of physiological and academic medicine at high altitude and low oxygen. Qinghai diagnostic criteria for selecting patients with confirmed chronic mountain sickness; 3. sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. no any clinical symptoms and the laboratory check positive indicators who; 2. live in elevation 3,000 m following of crowd; 3. emigrated 1 years following has acute, and Asia acute plateau syndrome disease who; 4. exists can caused or aggravated low oxygen blood syndrome of chronic respiratory disease or some can caused low oxygen blood syndrome of primary heart brain vascular disease heart lung disease by caused of following made sexual RBC increased syndrome and the authenticity RBC increased syndrome patients; 5. bone marrow, and And consistent with Myeloproliferative Disorders such as fusion genes (tumor) or other patients with diagnosis of proliferation of malignant hematological diseases.

Design outcomes

Primary

MeasureTime frame
eotaxin;eotaxin-2;G-CSF;GM-CSF;I-309;IFN-?;IL-1a;IL-1ß;IL-2;IL-4;IL-6;IL-6 sR;IL-7;IL-8;IL-10;IL-11;IL-12 P40;IL-12 P70;IL-13;IL-15;IL-16;IL-17;PDGF-BB;MCSF;MIP-1a;MIP-1ß;MIP-1d;TIMP-1;TIMP-2;TNF-a;TNF-ß;sTNFR ?;sTNFR;sTNFR ?;—

Secondary

MeasureTime frame
MCP-1;RANTES;—

Countries

China

Contacts

Public ContactPeiyan Kong

Second Affiliated Hospital of Third Military Medical University

peiyankong@aliyun.com+86 23 68774209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026